Platelet crossmatch studies were done using Capture-P, Ready-Screen platelet crossmatch kit for detection of immunoglobulin G antibodies to platelets (anti-human platelet antigen-1 [HPA-1] and anti-HPA-2) on NEO solid-phase automated system (Immucor, USA), and compatible platelets were chosen for transfusion. Transfusion with crossmatch compatible platelets yielded an increment of platelet count from 39000/μl to 75000/μl which raised the suspicion of neonatal alloimmune thrombocytopenia (NAIT). Further, the mother's plasma suspected to contain antiplatelet antibodies was crossmatched with the baby's platelets and the father's (husband's) platelets. The results of crossmatch are enumerated in Table 1 . The patient was treated with intravenous immunoglobulin (IVIg) in a dose of 1 g/kg once daily for 2 days. Gradually, the platelet count improved. He was discharged home well on full feeds.
Introduction
N eonatal Alloimmune Thrombocytopenia should be considered in any neonate who presents with severe thrombocytopenia at birth or shortly thereafter, particularly in the absence of other risk factors, clinical signs, or abnormalities in the physical examination. Diagnosis is mostly based on clinical suspicion. In resource limited settings platelet crossmatch studies help as a pointer to diagnosis and in providing compatible platelets.
Case Report
A 13-day-old male baby was born to a primi mother at 35 weeks of gestation by Cesarean section for breech presentation. His birth weight was 2800 g. The perinatal period was uneventful, and his Apgar score was 6 and 9 at 1 and 5 min, respectively. On day 3 of life, he developed respiratory distress requiring newborn intensive care unit. He was ventilated for the respiratory distress for 3 days and weaned off to room air. The complete blood count revealed thrombocytopenia (platelet count: 21000/μl) with normal white cell count and hemoglobin. His coagulation parameters were within normal limits. The direct antiglobulin test was positive. He received multiple platelet transfusions with both random-donor platelets and single-donor platelets (SDPs) with no improvement in platelet count.
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The true incidence of the disease is likely higher, however, since milder cases might go undetected and the most severe cases lead to intrauterine death. Intrauterine death or intracranial hemorrhage (ICH) may occur as early as at 14-16-week gestation, resulting in a relatively high incidence of intrauterine ICH (>10%). The overall incidence of ICH (prenatal and postnatal) is particularly high in this population, affecting up to 20% of infants with NAIT. [3] [4] [5] [6] NAIT should be considered in any neonate who presents with severe thrombocytopenia at birth or shortly thereafter, particularly in the absence of other risk factors, clinical signs, or abnormalities in the physical examination.
In the present case, a diagnosis of NAIT was arrived based on the results of platelet crossmatch and after excluding other causes of respiratory distress and thrombocytopenia such as infections and septicemia. This was an otherwise healthy baby except for the sudden onset of thrombocytopenia. Posttransfusion purpura as the cause of thrombocytopenia was unlikely because the baby had thrombocytopenia even before the platelet transfusions were given. Platelet crossmatch results showed incompatibility between the mother's plasma and the baby's platelets and the husband's/father's platelets suggesting alloimmune thrombocytopenia. In the absence of platelet antigen typing, compatible platelets for transfusion were chosen by crossmatching SDP with maternal serum. Maternal platelets were not considered for transfusion, and crossmatching between the baby's plasma and the mother's platelets was not done.
Platelet antigen studies would have helped to pinpoint the nature of the platelet antibody but could not be performed due to the absence of platelet-specific laboratories in India.
Direct antiglobulin test positivity in the absence of clinical hemolysis was attributed to intravenous immunoglobulin administration.
The most common antibody implicated in NAIT is anti-HPA-1a; [7] HPA-1a (PL A1 )-negative phenotypes constitute 2% of North American population and 1% in Asians; therefore, theoretically, 1 in 50 live births (American) or 1 in 100 (Asian) population should have NAIT. However, the incidence is far less, estimated to occur in 1 in 1000-2000 births. [8] Maternal immunization to HPA-1a shows human-leukocyte antigen (HLA) restriction. HPA-1a-negative women who produce alloantibodies are almost exclusively HLADRB3*0101 or DQB1*0201. Most cases of NAIT are caused by alloantibodies to HPA-1a, HPA5b (Br a ), and HPA-15b (Gov a ). Other alloantigens implicated in NAIT are HPA-1b (PL A2 ), HPA-3a (Bak a ), HPA-3b (Bak b ), HPA-4a (Pen a ), HPA-4b (Pen b ), HPA-5a (Br b ), and HPA-15a (Gov b ). [9] In resource-limited settings, platelet crossmatch studies of newborns and mothers help as a pointer toward a diagnosis of NAIT. However, platelet antigen studies help in establishing a diagnosis. Transfusion of platelets crossmatched and compatible with the mother's plasma may help in better management and better clinical outcomes.
Conclusion
The first suspicion of NAIT usually arises when an otherwise normal newborn presents with thrombocytopenia with or without bleeding manifestations such as petechial hemorrhages, ecchymoses, or other bleeding symptoms. NAIT can be diagnosed clinically in most cases by exclusion of other causes of thrombocytopenia. Demonstrating incompatibility between the baby's serum and paternal platelets clinches the diagnosis even in the absence of HLA antigen studies. A normal platelet count in the mother ruled out immune thrombocytopenia.
Early diagnosis and treatment with IVIg or transfusion with crossmatched platelets is the key for better management of NAIT.
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